Clinical Trials · NCT05368857
DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Clinuvel (UK) Ltd.
- Enrollment
- 10
- Start date
- Jan 2022
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Change in UV photoproduct levels in UVR-exposed skin.